Company intelligence / Profile preview

DexTechnology

Uppsala, Uppsala County, Swedendextechnology.com ↗

Ownership: Private
Development stage: Other

Overview

OsteoDex, DexTech's lead candidate, has completed a successful phase II study in castration-resistant prostate cancer with bone metastases, demonstrating high tolerability and mild side effects. Other programs are at earlier stages. The company aims to out-license its drug candidates after phase II studies.

Therapeutic areas: OncologyEndocrinology
Modalities: Small moleculeCarbohydrate-drug conjugatePeptidesBiologic
Industry: Biotech

Partnerships

None publicly disclosed.

Beyond the preview

Go deeper on DexTechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DexTechnology.

Explore the full profile